Lymphoma, Solid Tumors
Conditions
Keywords
Tumor, Lymphoma, Zalypsis, PharmaMar, PM00104
Brief summary
Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to subjects with advanced malignant solid tumors or lymphoma.
Detailed description
Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to subjects with advanced malignant solid tumors or lymphoma. Secondary objectives are to determine the preliminary pharmacokinetics of PM00104, to evaluate the relationship between pharmacokinetics/pharmacodynamics and to evaluate the preliminary antitumor activity of PM00104. Dose-escalation guidelines will follow an accelerated phase I design for conventional cytotoxic agents in order to minimize the number of subjects treated at the subtoxic dose levels. The trial will be conducted in compliance with the protocol, Good clinical practice (GCP) and applicable regulatory requirements.
Interventions
DRUGPM00104
Intravenously over 1 hour daily for 5 days, every 3 weeks.
Sponsors
PharmaMar
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary written informed consent of the subject obtained before any study-specific procedure. 2. Histologically or cytologically confirmed malignant solid tumor or lymphoma. 3. Subjects with malignancies that are not otherwise curable or for which no effective standard therapy exists. 4. Age ≥ 18 years. 5. Subject with measurable or non-measurable disease using the RECIST criteria 6. Recovery from any drug-related adverse event related to previous treatment, excluding alopecia and NCI-CTCAE grade \< 2 peripheral neuropathy. 7. Laboratory values within 7 days prior to first infusion: * Platelet count ≥ 100 x109/L, hemoglobin ≥ 9 g/dL and absolute neutrophil count (ANC) ≥ 1.5 x109/L. * Alkaline phosphatase ≤ 2.5 x the upper limit of normal (ULN) (≤ 5 x ULN in case of extensive bone metastases) * Aspartate aminotransferase (AST): ≤ 2.5 x ULN * Alanine aminotransferase (ALT): ≤ 2.5 x ULN * Total bilirubin: ≤ 1.5 ULN, unless due to Gilbert's syndrome. * Creatinine: ≤ ULN, or calculated creatinine clearance: ≥ 60 mL/min (calculated from the Cockcroft-Gault formula; see Appendix III). * Albumin: ≥ 2.5 g/dL. * Partial thromboplastin within normal limits for the institution * International normalized ratio (INR) within normal limits for the institution (unless due to oral anticoagulation) 8. Performance status (ECOG) ≤ 1 9. Life expectancy ≥ 3 months. 10. Left ventricular ejection fraction (LVEF) within normal limits for the institution (LVEF of at least 50%). 11. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include complete abstinence, Intrauterine device, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository).
Exclusion criteria
1. Prior therapy with PM00104 2. Pregnant or lactating women. 3. Less than 4 weeks from radiation therapy (8 weeks in case of extensive prior radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy (6 weeks in case of nitrosourea, mitomycin C). 4. Prior high dose chemotherapy that needed bone marrow transplant support. 5. Subjects with untreated or uncontrolled brain or meningeal metastases. 6. Other relevant diseases or adverse clinical conditions: * Increased cardiac risk as defined by: * History or presence of unstable angina. * History or presence of myocardial infarction. * Congestive heart failure. * Symptomatic arrhythmia or any arrhythmia requiring ongoing treatment. * Abnormal ECG (i.e., patients with the following are excluded: QT prolongation-corrected QT interval \> 480 msec-, signs of cardiac enlargement or hypertrophy, bundle branch block, partial bundle branch blocks, signs of ischemia or necrosis, Wolff-Parkinson-White patterns). * History or presence of valvular heart disease. * Uncontrolled arterial hypertension despite optimal medical therapy. * Previous mediastinal radiotherapy. * Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m2 * History of significant neurological or psychiatric disorders. * Active infection. * Significant non-neoplastic liver disease (e.g., cirrhosis, chronic active hepatitis). * Significant non-neoplastic renal disease. * Immunocompromised subjects, including subjects known to be infected by human immunodeficiency virus (HIV). * Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) requiring relevant changes in medication within the last month or hospital admission within the last 3 months. * Any other major illness that, in the investigator's judgment, could substantially increase the risk associated with the subject's participation in this study. 7. Limitation of the subject's ability to comply with the treatment or to follow-up at a participating center. Subjects registered on this trial must be treated and followed at a participating center. 8. Treatment with any investigational product in the 30 days period prior to the first infusion. 9. Known hypersensitivity to any of the components of the drug product, including sucrose or potassium phosphate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients With Dose Limiting Toxicities (DLT) | During the first cycle (21 days) | DLTs were defined as follows: * Hematological adverse events: * Any grade 4 neutropenia (absolute neutrophil count (ANC) \< 0.5 x109/l) for longer than five days; * Any grade 4 neutropenia accompanied by fever (at least 38.5°C); * Any grade 4 neutropenia and sepsis or other severe infection; * Any grade 4 thrombocytopenia. * Any other grade 3/4 non-hematological adverse event (AE) and any increase of cardiac troponin I ≥0.1 ng/ml together with evidence of cardiac damage by electrocardiogram (ECG) or echocardiogram (ECHO), except for untreated nausea/vomiting or hypersensitivity reactions. * Decrease in left ventricular ejection fraction (LVEF) \> 20% compared to the patient's baseline value and/or LVEF \< 50% below normal limits for the institution. * Delay in the initiation of a subsequent dose exceeding two weeks due to drug related AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Best Tumor Response | every six weeks while on study, up to 2 years | Best tumor response was defined as the best response achieved during the study according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response (CR): disappearance of all lesions; Partial response (PR): ≥10% decrease in target lesion size or ≥15% decrease in tumor density; Disease progression (PD): ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; Stable disease (SD): none of the CR, PR, or PD criteria met; RECIST, |
Countries
United States
Participant flow
Recruitment details
Twelve patients were enrolled and 11 patients were treated between 9 May 2006 (first consent signed) and 10 September 2008 (last follow-up). The first dose of the first cycle was administered on 15 May 2006 and the last dose of the last cycle was administered on 20 June 2008
Participants by arm
| Arm | Count |
|---|---|
| Dose-level I PM00104: 0.053 mg/m2 | 1 |
| Dose-level II PM00104: 0.106 mg/m2 | 1 |
| Dose-level III PM00104: 0.212 mg/m2 | 3 |
| Dose-level IV PM00104: 0.318 mg/m2 | 3 |
| Dose-level V PM00104: 0.475 mg/m2 | 3 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Not treated | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Progressive disease | 1 | 1 | 2 | 3 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Dose-level I | Dose-level II | Dose-level III | Dose-level IV | Dose-level V | Total |
|---|---|---|---|---|---|---|
| Age, Continuous | 46 years | 56 years | 54 years | 66.0 years | 57 years | 56 years |
| ECOG PS PS 0 | 0 participants | 0 participants | 0 participants | 1 participants | 2 participants | 3 participants |
| ECOG PS PS 1 | 1 participants | 1 participants | 3 participants | 2 participants | 1 participants | 8 participants |
| Primary tumor Cervix adenocarcinoma | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Primary tumor Colorectal adenocarcinoma | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Primary tumor Head and neck carcinoma | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Primary tumor Pseudomyxoma peritoneii | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Primary tumor Soft tissue sarcoma | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 4 Participants |
| Primary tumor Unknown origin | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Prior chemotherapy 2-5 lines | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 2 Participants | 7 Participants |
| Prior chemotherapy ≥ 6 lines | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 4 Participants |
| Prior radiotherapy | 1 Participants | 0 Participants | 2 Participants | 2 Participants | 1 Participants | 6 Participants |
| Prior Surgery | 1 Participants | 0 Participants | 3 Participants | 3 Participants | 3 Participants | 10 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Caucasian | 1 Participants | 1 Participants | 3 Participants | 3 Participants | 2 Participants | 10 Participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 1 Participants | 3 Participants | 2 Participants | 7 Participants |
| Sex: Female, Male Male | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 1 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 11 |
| other Total, other adverse events | 11 / 11 |
| serious Total, serious adverse events | 5 / 11 |
Outcome results
Primary
Patients With Dose Limiting Toxicities (DLT)
DLTs were defined as follows: * Hematological adverse events: * Any grade 4 neutropenia (absolute neutrophil count (ANC) \< 0.5 x109/l) for longer than five days; * Any grade 4 neutropenia accompanied by fever (at least 38.5°C); * Any grade 4 neutropenia and sepsis or other severe infection; * Any grade 4 thrombocytopenia. * Any other grade 3/4 non-hematological adverse event (AE) and any increase of cardiac troponin I ≥0.1 ng/ml together with evidence of cardiac damage by electrocardiogram (ECG) or echocardiogram (ECHO), except for untreated nausea/vomiting or hypersensitivity reactions. * Decrease in left ventricular ejection fraction (LVEF) \> 20% compared to the patient's baseline value and/or LVEF \< 50% below normal limits for the institution. * Delay in the initiation of a subsequent dose exceeding two weeks due to drug related AEs
Time frame: During the first cycle (21 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose-level I | Patients With Dose Limiting Toxicities (DLT) | 0 participants |
| Dose-level II | Patients With Dose Limiting Toxicities (DLT) | 0 participants |
| Dose-level III | Patients With Dose Limiting Toxicities (DLT) | 0 participants |
| Dose-level IV | Patients With Dose Limiting Toxicities (DLT) | 0 participants |
| Dose-level V | Patients With Dose Limiting Toxicities (DLT) | 0 participants |
Secondary
Overall Best Tumor Response
Best tumor response was defined as the best response achieved during the study according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response (CR): disappearance of all lesions; Partial response (PR): ≥10% decrease in target lesion size or ≥15% decrease in tumor density; Disease progression (PD): ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; Stable disease (SD): none of the CR, PR, or PD criteria met; RECIST,
Time frame: every six weeks while on study, up to 2 years
Population: 11 patients were evaluable for antitumor activity
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose-level I | Overall Best Tumor Response | SD | 0 Participants |
| Dose-level I | Overall Best Tumor Response | PD | 1 Participants |
| Dose-level II | Overall Best Tumor Response | SD | 0 Participants |
| Dose-level II | Overall Best Tumor Response | PD | 1 Participants |
| Dose-level III | Overall Best Tumor Response | SD | 3 Participants |
| Dose-level III | Overall Best Tumor Response | PD | 0 Participants |
| Dose-level IV | Overall Best Tumor Response | PD | 1 Participants |
| Dose-level IV | Overall Best Tumor Response | SD | 2 Participants |
| Dose-level V | Overall Best Tumor Response | SD | 1 Participants |
| Dose-level V | Overall Best Tumor Response | PD | 2 Participants |